Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Inspire Medical Systems enters the final stretch before its November 2 earnings with short interest climbing sharply on the week, a fresh bearish initiation from a major bank, and options traders positioned more bullishly than the fundamental picture might suggest.
Short interest is the most active story in the data this week. Bears added roughly 8.5% more shares to their positions over seven days, pushing short interest to 14.6% of free float, just under 4.25 million shares. That is a meaningful level for a medical device name of this size. The lending market remains loose, though: availability has tightened considerably, falling more than 52% on the week to 603%, which means there are roughly six shares available to borrow for every one already borrowed. Borrowing costs have also spiked, up 165% on the week to 0.51%, though the absolute level remains low enough to impose little friction on new short positions. Cost to borrow was running around 0.19% a week ago, so the direction of travel is notable even if the rate itself stays modest.
Options positioning tells a contrasting story. Call volume is dominating, with the put/call ratio at 0.56, nearly a full standard deviation below its 20-day mean of 0.87. That reading places options traders on the bullish side of their recent range, a sharp reversal from late September when the ratio was consistently above 1.20 as the stock was still digesting its guidance cut. The shift since early October is striking: three consecutive sessions with PCR below 0.56. Whether that reflects speculative call-buying ahead of November results or hedged institutional positioning is unclear from the data alone, but the directional move away from puts is hard to ignore.
The Street itself is divided, and the most notable recent move leans negative. Barclays initiated coverage this week with an Underweight rating and a $65 price target, sitting just below the current price of $68.20. That initiation gives formal voice to the bear case, which centres on Inspire's guidance reset: the company slashed its 2026 revenue outlook to $950 million to $1,000 million from the prior $1,003 million to $1,013 million range, citing reimbursement and coding uncertainty that has specifically chilled ENT specialist activity. On the other side, Freedom Capital Markets held its Buy rating and $97 target, and RBC Capital raised its target from $60 to $75 while staying at Sector Perform. Stifel also raised its Buy target to $80 in September. The spread between the $65 floor and the $97 ceiling captures the genuine disagreement about whether the reimbursement headwind is temporary or structural. The PE multiple has expanded modestly over the past month to 46x, reflecting the stock's partial recovery off its lows, while EV/EBITDA has eased slightly to 8.6x. Factor scores are weighted against the bulls: the EPS surprise rank sits at just the 10th percentile, and the forward EPS growth rank at 5th, consistent with a company navigating a downward estimate revision cycle.
Institutional flows add one detail worth noting. BlackRock added nearly 1.2 million shares in the most recently reported period and now holds 16.4% of shares, its 13G/A filed in late July reflecting a stake that grew from 11.3% to 14.4%. Soleus Capital appeared as a fresh holder at 6.7% of shares as of June, and AQR also built a new position of 6.4% over the same period. The accumulation by these names through the summer suggests some institutional buyers were active during the drawdown, though positions are as-last-disclosed and the picture will update at next quarter's filings. On the other side, FMR and Wasatch have both trimmed sharply from above 5% to sub-3% and sub-1% respectively, and Marc Stad exited entirely. Insider activity is limited to a single open-market sale of 963 shares at $59.55 in August by an insider listed under "See Remarks," a modest transaction that carries little informational weight.
Wikipedia attention for the stock spiked to a z-score of 4.1 against its own 90-day history as of late September, a retail attention signal worth contextualising: it follows a meaningful price recovery from the stock's lows and the guidance-cut headlines, and is an attention measure only, with no measured link to the company's reported figures.
The November 2 print is the pivot point: the core question for that release is whether the reimbursement and coding dynamics that drove the guidance cut have stabilised, worsened, or begun to clear, and Barclays' entry this week with a price target below the current price sets a concrete bearish marker against which that answer will be measured.
See the live data behind this article on ORTEX.
Open INSP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
